meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population
5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant
1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative
1
mNSCLC - L2 - PDL1 positive
7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population
1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population
1
squamous - mNSCLC - L2 - PDL1 positive
<span style="margin-left: 0em;">chemotherapy</span>
<span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">Immune checkpoint association</span>
<span style="margin-left: 2em;">durvalumab plus tremelimumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (1)
progression or deaths (PFS) (1)
objective responses (ORR) (1)
DOR (1)
AE (any grade) (1)
TRAE (any grade) (1)
SAE (any grade) (1)
TRAE (grade 3-4) (1)
AE (grade 3-4) (1)
TRAE leading to death (grade 5) (1)
TRAE leading to discontinuation (any grade) (1)
AE leading to death (grade 5) (1)
AE leading to treatment discontinuation (any grade) (1)
Pruritus TRAE (grade 3-4) (1)
Rash TRAE (grade 3-4) (1)
Diarrhoea TRAE (grade 3-4) (1)
Colitis TRAE (grade 3-4) (1)
Increased ALT TRAE (grade 3-4) (1)
Increase AST TRAE (grade 3-4) (1)
Hepatitis TRAE (grade 3-4) (1)
Hypothyroidism TRAE (grade 3-4) (1)
Hyperthyroidism TRAE (grade 3-4) (1)
Thyroiditis TRAE (grade 3-4) (1)
Fatigue TRAE (grade 3-4) (1)
Nausea TRAE (grade 3-4) (1)
Anaemia TRAE (grade 3-4) (1)
Decreased appetite TRAE (grade 3-4) (1)
Asthenia TRAE (grade 3-4) (1)
Dyspnoea TRAE (grade 3-4) (1)
Pyrexia TRAE (grade 3-4) (1)
Pruritic rash TRAE (grade 3-4) (1)
Pneumonitis TRAE (grade 3-4) (1)
Thrombocytopenia TRAE (grade 3-4) (1)
Neutropenia TRAE (grade 3-4) (1)
Vomiting TRAE (grade 3-4) (1)
Leucopenia TRAE (grade 3-4) (1)
Hypophysitis TRAE (grade 3-4) (1)
Increased lipase level TRAE (grade 3-4) (1)
Adrenal insufficiency TRAE (grade 3-4) (1)
Hypersensitivity TRAE (grade 3-4) (1)
Pancreatitis TRAE (grade 3-4) (1)
Myositis TRAE (grade 3-4) (1)
Weight decreased TRAE (grade 3-4) (1)
Peripheral oedema TRAE (grade 3-4) (1)
Stomatitis TRAE (grade 3-4) (1)
Hypertension TRAE (grade 3-4) (1)
Acute kidney injury TRAE (grade 3-4) (1)
Infusion-related reactions TRAE (grade 3-4) (1)
Pneumonia TRAE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for deaths (OS)
1
ARCTIC (DT ; study B ; PDL1<25%), 2020
Standard of Care (SoC)
durvalumab plus tremelimumab
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
Standard of Care (SoC)
durvalumab plus tremelimumab
Standard of Care (SoC)
---
NA
durvalumab plus tremelimumab
NA
---
pathologies: 217 - treatments: 634,861
result logic
×
Study list
